Normal view MARC view ISBD view

Quantitative risk-benefit analysis of natalizumab.

Steiner, Israel

Quantitative risk-benefit analysis of natalizumab. [electronic resource] - Neurology May 2009 - 1791-2; author reply 1791-2 p. digital

Publication Type: Comment; Letter

ISSN: 1526-632X

Standard No.: 10.1212/01.wnl.0000347020.85704.36 doi

Subjects--Topical Terms:
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Clinical Trials as Topic
Humans
Leukoencephalopathy, Progressive Multifocal--etiology
Multiple Sclerosis, Relapsing-Remitting--complications
Natalizumab
Risk Factors

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)